Objective: To evaluate preoperative body composition, including skeletal muscle and visceral adipose tissue, and to clarify the impact on outcomes after hepatectomy for hepatocellular carcinoma (HCC). Background: Recent studies have indicated that sarcopenia is associated with morbidity and mortality in various pathologies, including cancer, and that obesity or visceral adiposity represents a significant risk factor for several cancers. However, the impact of sarcopenic obesity on outcomes after hepatectomy for HCC has not been fully investigated. Methods: We retrospectively analyzed 465 patients who underwent primary hepatectomy for HCC between April 2005 and March 2015. Skeletal muscle mass and visceral adipose tissue were evaluated by preoperative computed tomography to define sarcopenia and obesity. Patients were classified into 1 of 4 body composition groups according to the presence or absence of sarcopenia and obesity. Results: Body composition was classified as nonsarcopenic nonobesity in 184 patients (39%), nonsarcopenic obesity in 219 (47%), sarcopenic nonobesity in 31 (7%), and sarcopenic obesity in 31 (7%). Compared with patients with nonsarcopenic nonobesity, patients with sarcopenic obesity displayed worse median survival (84.7 vs. 39.1 mo, P ¼ 0.002) and worse median recurrence-free survival (21.4 vs. 8.4 mo, P ¼ 0.003). Multivariate analysis identified sarcopenic obesity as a significant risk factor for death (hazard ratio [HR] ¼ 2.504, P ¼ 0.005) and HCC recurrence (HR ¼ 2.031, P ¼ 0.006) after hepatectomy for HCC. Conclusion: Preoperative sarcopenic obesity was an independent risk factor for death and HCC recurrence after hepatectomy for HCC.
H epatocellular carcinoma (HCC) is one of the most common cancers around the world. 1 Although advances in preoperative diagnosis and management of HCC have improved overall survival (OS) and recurrence-free survival (RFS) after hepatectomy for HCC, the postoperative recurrence rate remains high even among patients who undergo curative resection. 2 Sarcopenia was initially described by Rosenberg in 1989 as an age-related decrease in muscle mass. 3 In 2010, the European Working Group on Sarcopenia in Older People recommended that the definition of sarcopenia include both low muscle mass and low muscle strength or function. 4 Sarcopenia is currently defined as a syndrome characterized by progressive and generalized loss of skeletal muscle mass and strength, and many studies have described sarcopenia as associated with morbidity and mortality in various pathologies, including several cancers. [5] [6] [7] [8] Our previous studies have identified preoperative low muscle quality as an independent risk factor for poor outcomes after hepatectomy for HCC. 9, 10 Recent studies have also concluded that obesity represents a significant risk factor for various health disorders, including type 2 diabetes mellitus, hypertension, cardiovascular disease, nonalcoholic steatohepatitis, and several cancers, including HCC. [11] [12] [13] [14] Moreover, sarcopenic obesity, as the state of being both obese and sarcopenia, has attracted much attention and recent studies have described sarcopenic obesity as a poor prognostic factor among patients with cirrhosis. 15, 16 However, the impact of preoperative sarcopenic obesity on outcomes in patients undergoing hepatectomy for HCC has yet to be fully investigated. The present study therefore aimed to evaluate preoperative body composition, including skeletal muscle and visceral adipose tissue, and to clarify the impact on outcomes after hepatectomy for HCC.
METHODS

Patients
A total of 522 patients underwent primary hepatectomy for HCC at Kyoto University Hospital between April 2005 and March 2015. Fifty-seven patients who did not undergo preoperative plain computed tomography (CT) at the umbilical level were excluded from this study. As a result, 465 patients (367 males, 98 females) were enrolled in this study. All the study protocols were approved by the Ethics Committee of Kyoto University and all the procedures were conducted in accordance with the Declaration of Helsinki of 1996.
Image Analysis
In accordance with previous studies, [17] [18] [19] we analyzed skeletal muscle and visceral adipose tissue from the latest preoperative unenhanced CT images (Aquillion 64; Toshiba Medical Systems, Tochigi, Japan). We measured cross-sectional skeletal muscle area at the level of the third lumbar vertebra (L3) and cross-sectional visceral adipose tissue area at the level of the umbilicus. Skeletal muscle area included the psoas, paraspinal (erector spinae, multifidus, and quadratus lumborum), and abdominal wall muscles (transversus abdominis, external and internal obliques, and rectus abdominis). Skeletal muscle and visceral adipose tissue were identified and quantified in Hounsfield units (HU) using an AquariusNET Server (TeraRecon, San Mateo, CA). A threshold range of À29 to 150 HU was used to define skeletal muscle, and a range of À150 to À50 HU was used to define visceral adipose tissue (Fig. 1A, B) .
The quantity of skeletal muscle was evaluated by skeletal muscle index (SMI), calculated by normalizing the cross-sectional areas of skeletal muscle in centimeters squared by the height of the patient in meters squared. Low SMI was regarded as a proxy for low skeletal muscle mass, and thus sarcopenia. SMI differs significantly between males and females, and we have recently established sexspecific cutoff values using data from 657 healthy donors for living donor liver transplantation (LDLT) between 2005 and 2016. 20 Cutoff values for SMI were defined as 40.31 cm 2 /m 2 in males and 30.88 cm 2 /m 2 in females. Obesity was considered present if the visceral adipose tissue area was ! 100 cm 2 in both males and females. This value is widely used as a cutoff to define sarcopenic obesity in Asian populations and is diagnostic of visceral fat obesity and consequently metabolic syndrome in Japan. [21] [22] [23] Patients were classified into 1 of 4 body composition categories according to the presence or absence of sarcopenia and obesity: nonsarcopenic nonobesity (NN), nonsarcopenic obesity (NO), sarcopenic nonobesity (SN), and sarcopenic obesity (SO).
Postoperative Morbidity
Data on postoperative morbidities were collected. The severity of morbidities was graded in accordance with the Dindo-Clavien classification. 24 Major morbidities were defined as any morbidities of Clavien grade ! III.
Analyzed Parameters
OS and RFS rates after hepatectomy for HCC were investigated in each group. Prognostic factors were analyzed using the following variables: patient age, sex, body mass index (BMI), original disease, platelet count, indocyanine green retention test at 
Statistical Analysis
Continuous variables are presented as mean AE standard deviation, and were nonparametrically analyzed using the Mann-Whitney U test. Categorical variables were compared using the x 2 test or Fisher exact test, as appropriate. Cumulative OS rates were calculated using Kaplan-Meier methods, and differences between curves were evaluated using the log-rank test. Any variable identified as significant (P < 0.050) or showing a value of P < 0.100 in univariate analysis with the abovementioned tests was considered a candidate for multivariate Cox regression analysis, and the results are shown as hazard ratios (HRs) with 95% confidence interval (CI). Values of P < 0.050 were considered significant. All statistical data were generated using JMP version 11.2 software (SAS Institute, Cary, NC) and Prism 6 software (GraphPad Software, La Jolla, CA).
RESULTS
Patient Characteristics
The clinical characteristics of patients in each group are shown in Table 1 . A total of 465 eligible patients were divided into the 4 body composition categories as follows: NN group, n ¼ 184 (39.5%); NO group, n ¼ 219 (47.1%); SN group, n ¼ 31 (6.7%); and SO group, n ¼ 31 (6.7%). Significant differences in patient age (P < 0.001), sex (P < 0.001), BMI (P < 0.001), original disease (P < 0.001), presence of hypertension (P < 0.001), and dyslipidemia (P ¼ 0.006) were seen between the 4 body composition categories. Patients in the SO group were older, more frequently male, and less frequently with hepatitis B or C compared with patients in other groups. Tumor-related factors, including tumor size, number of tumors, MVI, tumor differentiation, and TNM stage, and surgical factors, including surgical procedure and blood loss, did not differ significantly between the 4 groups.
Postoperative Morbidity
The overall morbidity rate was 35.1% (n ¼ 163); the morbidity rate of each group was: NN group 31.0% (n ¼ 57), NO group 35.6% (n ¼ 78), SN group 48.4% (n ¼ 15), and SO group 41.9% (n ¼ 13) (Table 1 ). There were no significant differences in the morbidity rate between the 4 body composition categories (P ¼ 0.218). On the other hand, the major morbidity rate was 20.1% (n ¼ 97); the major morbidity rate of each group was: NN group 16.9% (n ¼ 31), NO group 20.1% (n ¼ 44), SN group 38.7% (n ¼ 12), and SO group 32.3% (n ¼ 10), with significant differences between the 4 categories (P ¼ 0.016). The overall morbidity rate and major morbidity rate tended to be lower in the latter half of the study period (April 2010-March 2015) than in the former half of the study period (April 2005-March 2010) (P ¼ 0.057 and P ¼ 0.093, respectively). FIGURE 1. Cross-sectional computed tomography images at the third lumbar vertebra level (A), and at the umbilical level (B). The red shadows show the skeletal muscle areas, which were identified and quantified using À29 to 150 HU. The green shadows show the visceral adipose tissue areas, which were quantified using À150 to À50 HU. (Fig. 2 A) . The 1-and 3-year RFS rates in patients with NN, NO, SN, and SO were 64.4% and 37.8% versus 64.9% and 38.1% versus 52.7% and 31.5% versus 33.8% and 19.3%, respectively (Fig. 2 B) . The OS and RFS rates after hepatectomy for HCC were significantly lower in the SO group than in the NN group (P ¼ 0.002, P ¼ 0.003, respectively; Fig. S1A , S1B, http://links.lww.com/SLA/B332). OS and RFS rates in the NO and SN groups did not differ significantly from those in the NN group (P ¼ 0.456, P ¼ 0.170, and P ¼ 0.685, P ¼ 0.660, respectively; Figure 2A , B). Table 2 shows the results of uni-and multivariate analyses of OS among patients who underwent hepatectomy for HCC. On multivariate analysis, poor differentiation (HR, 1.945; 95% CI, 1.167-3.199; P ¼ 0.011), advanced TNM stage (HR, 2.478; 95% CI, 1.313-3.940; P ¼ 0.003), major morbidity (HR, 1.906; 95% CI, 1.130-3.143; P ¼ 0.016), and sarcopenic obesity (HR, 2.504; 95% CI, 1.336-4.499; P ¼ 0.005) were independent risk factors for death after hepatectomy for HCC ( Table 2) .
TABLE 1. Characteristics of Patients Included in the Study
Characteristic Total (n ¼ 465) NN (n ¼ 184) NO (n ¼ 219) SN (n ¼ 31) SO (n ¼ 31) P Patient
Risk Factors for Poor Outcomes in Patients Undergoing Hepatectomy for HCC
The results of uni-and multivariate analyses of recurrencefree survival are shown in Table 3 . Multivariate analysis identified advanced TNM stage (HR, 2.972; 95% CI, 1.957-4.526; P < 0.001) and sarcopenic obesity (HR, 2.031; 95% CI, 1.233-3.222; P ¼ 0.006) as independent risk factors for HCC recurrence (Table 3) .
DISCUSSION
This retrospective study identified preoperative sarcopenic obesity as a significant risk factor associated with poor prognosis among patients who had undergone hepatectomy for HCC.
Recent studies have described sarcopenia as associated with morbidity and mortality in various pathologies, including several cancers. [5] [6] [7] Preoperative low skeletal muscle mass was found to be an independent prognostic factor for mortality and recurrence after hepatectomy for HCC. 8, 25 Furthermore, we recently reported that preoperative low skeletal muscle quality was an independent risk factor for poor outcomes after hepatectomy for HCC.
9,10 These findings demonstrated that preoperative low muscularity (muscle mass and muscle quality) was closely associated with morbidity and mortality after hepatectomy for HCC. In addition, obesity represents a significant risk factor for various health disorders, including type 2 diabetes mellitus, hypertension, cardiovascular disease, nonalcoholic steatohepatitis, and several cancers. [11] [12] [13] [14] In the US population, overweight and obesity have been associated with the risk of death from all cancers. 12 A recent study showed that visceral obesity, defined as a high visceral to subcutaneous adipose tissue area ratio (VSR), was associated with poor outcomes in patients with HCC. 18 Recent studies also described that sarcopenic obesity, the state of being both obese and sarcopenic, has attracted substantial attention as a prognostic factor for poor outcomes in patients with solid tumors 17, 26 or cirrhosis. 15, 16 However, there have been no studies fully investigating sarcopenic obesity, and its influence on outcomes after hepatectomy for HCC remains unclear. As far as we know, this present retrospective study is the first to investigate the impact of sarcopenic obesity on outcomes in patients undergoing hepatectomy for HCC.
This study included cases of patients for 10 years and meanwhile, progress had taken place in surgical procedures and curative treatments for HCC. Therefore, we investigated outcomes after hepatectomy for HCC by dividing the study period into 2 subperiods, the former half and the latter half. The overall morbidity and major morbidity rates tended to be lower in the latter subperiod than in the former subperiod (P ¼ 0.057 and P ¼ 0.064, respectively), but the OS and RFS rates did not differ significantly between the 2 subperiods (P ¼ 0.275 and P ¼ 0.398, respectively).
In the present study, patients were classified into 1 of 4 body composition categories: nonsarcopenic nonobesity, nonsarcopenic obesity, sarcopenic nonobesity, and sarcopenic obesity. Sarcopenic nonobesity was not a negative prognostic factor. However, when patients were classified into 1 of 2 groups; sarcopenia and nonsarcopenia, the overall survival and recurrence-free survival rates were significantly lower in sarcopenic patients than in nonsarcopenic patients (P ¼ 0.005 and P ¼ 0.007, respectively). Moreover, multivariate analysis identified sarcopenia as a significant risk factor for death (HR, 1.825; 95% CI, 1.218-2.653; P ¼ 0.004) and HCC recurrence (HR, 1.479; 95% CI, 1.047-2.036; P ¼ 0.027) after hepatectomy for HCC. On the other hand, obesity alone was not a negative prognostic factor. By dividing the subjects into 4 groups, we were able to more accurately investigate an independent risk factor for death and HCC recurrence after hepatectomy for HCC.
In terms of the mechanisms through which sarcopenic obesity represents an independent risk for mortality and morbidity, associations among immunity, inflammation, and myokines and adipocytokines (such as adiponectin and leptin) are considered possibilities. [27] [28] [29] Recent studies have shown that skeletal muscle loss with increasing adiposity leads to increased levels of inflammatory adipokines such as leptin, tumor necrosis factor (TNF)-a, and interleukin (IL)-6, and to decreased concentrations of adiponectin or myokines such as IL-15. 30 In addition, leptin has been shown to promote HCC progression via tumor cells activating various growth and survival signaling pathways. 31 Similarly, accumulation of FIGURE 2. Overall survival rates after hepatectomy for HCC classified according to the 4-body composition categories (A). Recurrence-free survival rates after hepatectomy for HCC classified according to the 4-body composition categories (B).
visceral adipose tissue increases concentrations of TNF-a, IL-6, and monocyte chemoattractant protein (MCP)-1, and decreases adiponectin. 32 Furthermore, excess visceral adipose tissue is strongly associated with increased insulin resistance. 33 All these changes are associated with progression of HCC. Sarcopenic obesity, in which severe obesity and low muscle mass are present concomitantly, represents the worst scenario, combining as it does the health risks of both obesity and depleted lean mass. On the basis of these things, sarcopenic obesity may be linked to poor outcomes after hepatectomy for HCC through various mechanisms.
Preoperative interventions to improve body composition could plausibly lead to improved outcomes after hepatectomy for HCC. To improve body composition, several studies have recommended exercise (aerobic and resistance) in combination with adequate Variables included in the multivariate analysis were platelet count, Child-Pugh classification, AFP, DCP, tumor differentiation, TNM stage, surgical procedure, operative blood loss, and SO. Tumor size, number of tumor, and MVI were not included to avoid colinearity, as they are included in TNM stage.
protein (leucine-enriched amino acids) and energy intakes as a key component. 34 Various studies have reported that eicosapentaenoic acid (EPA) supplementation exerted positive effects on the maintenance of weight and lean body mass, and EPA could reduce inflammation. [35] [36] [37] In a mouse model, regular exercise decreased liver tumor development and stimulated the phosphorylation of AMPK and its substrate, raptor, which decreased the kinase activity of mTOR. 38 We have previously described that in patients undergoing LDLT, preoperative nutritional therapy including branched-chain amino acids (BCAAs) significantly improved overall survival among patients showing preoperative sarcopenia. 39 On the basis of such findings, we are now conducting a prospective study to evaluate the Variables included in the multivariate analysis were AFP, DCP, tumor differentiation, TNM stage, surgical procedure, operative blood loss, and SO. Tumor size, number of tumor, and MVI were not included to avoid colinearity, as they are included in TNM stage.
effects of preoperative exercise and nutritional therapy on body composition and postoperative outcomes after hepatectomy for HCC. We hope that such investigations will improve outcomes after hepatectomy for HCC.
The present study had several limitations. First, the possibility of selection bias in patient inclusion in the study group must be considered, as 57 patients (10.9%) were excluded from this study. We excluded patients for the sole reason of having undergone no CT at the umbilical level (in all cases, L3 level was higher than the umbilical level). However, perioperative factors did not show any significant differences between the excluded population and the study group. We therefore consider that little actual selection bias was present in terms of patient inclusion in the study. Second, we have to keep in mind whether our cutoff values are appropriate to define sarcopenia and obesity. Several studies have established definitions for sarcopenia according to different criteria, and the need for definitive criteria remains. [40] [41] [42] The present study used cutoff values for SMI based on data from healthy donors for LDLT, 20 and those values were similar to findings from a recent study in Japan. 43 Our cutoff values were therefore considered likely to be adequate to define sarcopenia, at least for Japanese populations. On the other hand, obesity is generally defined as BMI ! 25 kg/m 2 and visceral fat obesity or metabolic syndrome as visceral adipose tissue area ! 100 cm 2 in Japan. 23 In the present study, the prevalence of obesity differed according to the use of BMI or visceral adipose tissue area. According to BMI, 117 patients (25.2%) were classifiable as obese, compared with 250 patients (53.8%) according to visceral adipose area. As an indirect measurement of adipose tissue, BMI cannot accurately account for differences in fat distribution. Indeed, BMI did not identify more than half of the patients with excess visceral adipose tissue in the present study. In this study, obesity was defined as a visceral adipose tissue area ! 100 cm 2 in both sexes, but visceral adipose tissue area does differ significantly between males and females (P < 0.001; Fig. S2 , http://links.lww.com/SLA/B332). Further investigations are therefore necessary.
In conclusion, preoperative sarcopenic obesity represented an independent risk factor for death and HCC recurrence after hepatectomy for HCC. Body composition can potentially be used as a prognostic factor in patients undergoing hepatectomy for HCC.
